In our cohort of patients, having normal (similar to HC) plasma HGF and Eotaxin/CCL11 levels and low plasma EGF and MIP-1β/CCL4 levels were prognostic risk factors for being classified as a progressive patient with MS (SP-MS or PP-MS). This evidence concerns the gene HGF and myeloid sarcoma.